Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.38 |
| ▸ | ABCC9 | O60706 | 3/20 | 0.34 |
| ▸ | ABCC8 | Q09428 | 3/20 | 0.34 |
| ▸ | KCNJ11 | Q14654 | 3/20 | 0.34 |
| ▸ | KCNJ8 | Q15842 | 3/20 | 0.34 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.31 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.31 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.31 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.31 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.31 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2656693 | 0.85 | PDE5A (0.34) | — | |
| SCHEMBL2662169 | 0.82 | MAPK1 (0.37) | ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL2660243 | 0.81 | — | — | |
| SCHEMBL2660241 | 0.80 | ABCC9 (0.33) | ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL2655216 | 0.80 | HRH4 (0.42) | MAPKAPK2ROCK2 | |
| SCHEMBL2658326 | 0.78 | GABRG2 (0.37) | MAPKAPK2 | |
| SCHEMBL2660127 | 0.76 | SCN9A (0.35) | — | |
| SCHEMBL2657245 | 0.76 | SCN9A (0.35) | — | |
| SCHEMBL2660129 | 0.76 | SCN9A (0.35) | — | |
| SCHEMBL2655608 | 0.73 | LMNA (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2176263-A2 | FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS | AstraZeneca AB (SE) | 2010-04-21 | — | — | EP | disclosed |
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| WO-2008155572-A2 | FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS | ASTRAZENECA AB (SE) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | COMT, BACE1, BDNF | MAPKAPK2 3690/4885ABCC9 4403/4885ABCC8 1576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.